Anabolic steroidAndrogenProhormoneDHT-derivedNon-aromatisingOral

1-DHEA (1-Androsterone precursor)

Also known as 1-Androstene-3b-ol,17-one · 1-Andro · delta-1-DHEA

Written by enwyReviewed 5 Aug 20262 sources0 comments

A popular post-2014-scheduling-era prohormone that converts to 1-androsterone and ultimately 1-testosterone, a non-aromatising DHT-derived androgen. Prized in the community for 'dry' lean gains without estrogen conversion, but suppressive and unstudied in humans. DASCA-scheduled in the US.

01 Overview

1-DHEA (1-androstene-3-beta-ol-17-one) is a 1-ene DHEA analog whose active downstream metabolite is 1-testosterone (dihydroboldenone), a potent non-aromatising androgen derived from the DHT structural class. It became one of the most widely sold prohormones after the first prohormone bans.

Because the end product cannot aromatise, users report lean, 'dry' gains with reduced water retention, at the cost of DHT-type side effects and notable suppression. There are essentially no controlled human trials; the profile is inferred from 1-testosterone pharmacology and user reports. It is listed as a controlled anabolic steroid.

02 Mechanism

Converted via 3-beta-HSD and 17-beta-HSD to 1-androsterone and then 1-testosterone (dihydroboldenone), a non-aromatising, 5-alpha-reductase-resistant androgen.

03 Dosing

Tier	Dose	Route	Notes
Community-typical	100–330 mg/day	Oral	Reported prohormone dosing; not medically validated.

Ester comparison

Ester	Half-life	Injection freq.	Testosterone by mass

04 Effects

Effect	Magnitude	Evidence
Dry lean mass and strength gainsUsers report steady lean gains without water retention; no controlled human data exist.	~2-4 kg lean over a cycle (reported)	Anecdotal
No estrogen conversion1-testosterone does not aromatise, so estrogenic side effects are absent.	Non-aromatising	Preclinical

05 Side effects

Effect	Severity	Frequency	Evidence	Countermeasures
Lethargy and reduced enduranceFatigue and cardiovascular endurance drop are frequently reported on 1-testosterone precursors.	Moderate	Commonly reported	Anecdotal
HPTA suppressionMarked suppression of endogenous testosterone requiring recovery support.	Moderate	Near-universal	Anecdotal

06 Legal status

United States

Schedule III controlled (DASCA 2014)

Anabolic steroid under the Designer Anabolic Steroid Control Act. · as of Jan 2026

07 References

1-Testosterone pharmacology (dihydroboldenone)Steroids, review

Designer Anabolic Steroid Control Act of 2014US Public Law 113-260

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.